MTOR and non-small cell lung carcinoma: Moreover preclinical evidence shows that inhibitors of PI3K or mTOR can restore sensitivity in breast cancer, non-small-cell lung cancer and glioblastoma cells resistant to biologic and cytotoxic drugs [35].